IPP Bureau
AbbVie and Scripps Research plan to develop anti-viral for Covid-19
By IPP Bureau - March 15, 2022
The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation
Zolgensma used pre-symptomatically enables kids to stand and walk
By IPP Bureau - March 14, 2022
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Ascletis increases ritonavir production capacity to 530 million tablets a year
By IPP Bureau - March 14, 2022
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
Draft policy on medical devices released
By IPP Bureau - March 14, 2022
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Roche Diagnostics India wins Frost & Sullivan 2021 India leadership award
By IPP Bureau - March 14, 2022
Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
USFDA approves Zydus’ Colestipol Hydrochloride tablets
By IPP Bureau - March 14, 2022
It is only the second generic application approved by the USFDA
Alembic receives USFDA tentative approval for hypertension drug
By IPP Bureau - March 14, 2022
Macitentan tablets, 10 mg have an estimated market size of US $ 797 million for twelve months ending Dec 2021 according to IQVIA
SPAG appoints Ritika Jauhari as President- Strategy & New Business
By IPP Bureau - March 14, 2022
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
Clarivate deals report highlights emerging trends in biopharma deal-making
By IPP Bureau - March 14, 2022
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Guardant Health receives regulatory approval for Guardant360 CDx in Japan
By IPP Bureau - March 14, 2022
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Illumina and Trivitron collaborate for next-generation sequencing in India
By IPP Bureau - March 14, 2022
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
Krsnaa Diagnostics appoints Dr Ravinder Sethi as Chief Operating Officer
By IPP Bureau - March 14, 2022
He was earlier associated with leading industry players like Hindustan Unilever, TATA Communications, Dr. Lal Path Labs, Oncquest and Metropolis Healthcare
USFDA clears Niramai's breast thermography device
By IPP Bureau - March 14, 2022
The SMILE-100 System is a breast thermography device that helps healthcare personnel review, measure and analyze thermally significant indications in the breast region
Applications for PLI in bulk drugs extended till March 31st 2022
By IPP Bureau - March 14, 2022
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Corbevax to be administered to children between 12-14 years
By IPP Bureau - March 14, 2022
Govt announces vaccination programme for kids and those above 60 years of age
